🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Hypertension, Portal

    phase 2 small molecule completed

    1 trial

  2. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  3. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial

  4. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  5. GSBR-1290

    Structure Therapeutics

    Overweight or Obesity

    phase 2 small molecule completed

    1 trial

  6. GSK influenza virus H5N1 vaccine 1557484A

    United Therapeutics Europe Ltd

    Influenza

    phase 2 mab terminated

    1 trial

  7. GVM±R regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. GW679769

    GlaxoSmithKline

    Postoperative Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  9. GX-03

    Turn Therapeutics

    Eczema Atopic Dermatitis

    phase 2 other active

    1 trial

  10. GX-03

    Turn Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  11. Galinpepimut-S + Montanide + GM-CSF

    United Therapeutics Europe Ltd

    Malignant Pleural Mesothelioma

    phase 2 mab completed

    1 trial

  12. Gallium Ga 68 Gozetotide

    United Therapeutics Europe Ltd

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  13. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  14. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  15. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  16. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Sarcoma

    phase 2 small molecule terminated

    1 trial

  17. Gemcitabine

    Acrivon Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  19. Gemcitabine 100 mg/ml Concentrate for Solution for Infusion, 9-ING-41, Abraxane 5 mg/ml powder for dispersion for infusion.

    ACTUATE THERAPEUTICS, INC.

    Refractory Hematologic Malignancies or Solid Tumors

    phase 2 small molecule active

    1 trial

  20. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  21. Givinostat 75 mg capsules, Givinostat 100 mg capsules, Givinostat 50 mg capsules

    Italfarmaco S.p.A.

    Chronic myeloproliferative neoplasm

    phase 2 small molecule active

    1 trial

  22. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  23. Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion.

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  24. Gluten- and casein-free diet

    United Therapeutics Europe Ltd

    Autism

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources